Skip to main content
Premium Trial:

Request an Annual Quote

Aria Changes Name to Ariosa Diagnostics; Completes Clinical Validation of Prenatal Trisomy Test


Aria Diagnostics said this week that it has changed its name to Ariosa Diagnostics "to further distinguish and differentiate itself from other companies and products."

The company also said it has completed a clinical validation study for its Harmony Prenatal Test, a non-invasive test for common fetal trisomies. The test analyzes cell-free fetal DNA from maternal blood using targeted sequencing.

Ariosa plans to present more details on its test technology and data analysis at the American College of Medical Genetics annual meeting in Charlotte, NC, this week.

"The completion of our validation study is an important milestone as we prepare to bring the Harmony Prenatal Test to market," said Ken Song, Ariosa's CEO, in a statement. He said that the study results support the company's previous findings of highly accurate fetal trisomy detection, which were published in January in two medical journals — the American Journal of Obstetrics and Gynecology and Prenatal Diagnosis (CSN 2/1/2012).

Also in January, the company said that it plans to launch the test in the US in the first half of this year for under $1,000 (CSN 1/18/2012).

Ariosa is in litigation with Sequenom, which already has a similar test called MaterniT21 on the market. Sequenom sued the company earlier this year, claiming that it infringes one of its patents. Last month, Sequenom asked the court for a preliminary injunction against Ariosa, barring it from using its test (CSN 2/29/2012).

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.